with other carcinomas. A patient with Lynch syndrome has a specifi c germline mutation that increases the lifetime risk for colorectal cancer to 70% to 80%; in comparison, patients without these mutations have a 6% risk for sporadic cancer. 4 Mutations in the genes MSH2, MLH1, MSH6, PMS2, and EPCAM are associated with Lynch syndrome. 5 The genetic mutation that causes Lynch syndrome can be inherited from either parent (autosomal dominance), and carriers have a 50% chance of passing the gene to each of their offspring. Patients with Lynch syndrome can develop early-age onset of colorectal cancer (mean age is 43 years). In comparison, sporadic colorectal cancer usually occurs in patients over age 60 years. 6 Synchronous (simultaneous) or metachronous (subsequent) lesions are more prevalent in patients with Lynch syndrome. Compared with sporadic cancer, in Lynch syndrome, 70% to 80% of tumors are proximal to the splenic fl exure, a pattern that can aid in diagnosis ( Table  1) . Tumors are usually poorly differentiated and show mucin production. More importantly, a patient with Lynch syndrome is at risk for early onset of extracolonic cancers such as uterine, gastric, ovarian, pancreatic, ureter and renal pelvis, biliary tract, brain, and small bowel cancer, and sebaceous neoplasms or keratoacanthomas. 7 The lifetime cumulative risk of endometrial cancer for women with Lynch syndrome is 40% to 60%, which equals or exceeds their risk of colorectal cancer. 4 Diagnostic testing The Amsterdam criteria, created in 1990 and revised in 1999, followed a 3-2-1 rule, recommending testing in patients if:
• Three or more family members diagnosed with colorectal cancer and/or an extracolonic cancer, one of whom is a fi rst-degree relative of the other two • Two generations of the family diagnosed with cancer • One affected member diagnosed before the age of 50.
Although easy to understand, these criteria only detected about 39% of patients with a mutation. 8 The Revised Bethesda Guidelines (Table 2) , published in 2004, fail to identify 25% of patients with mutations. 8 Consequently, most hospitals perform universal screening for Lynch syndrome using immunohistochemistry testing of all patients with colorectal, small bowel, or endometrial cancer. 4 Tumors can be tested via immunohistochemistry and for microsatellite instability (phenotypic evidence that DNA mismatch repair is not functioning properly) to screen for Lynch syndrome. Microsatellites are noncoding areas on the genome that are repeated several times, and normally are constant from cell to cell within a person. Microsatellite instability is defi ned as variations in the number of repeated segments from cell to cell within a person. Patients also normally have two copies of the DNA mismatch repair genes, which function as tumor suppressor genes. If one gene is mutated and the other is damaged, tumor suppression does not occur and cancer cells can replicate.
Microsatellite instability and immunohistochemistry testing not only identify the likelihood of Lynch syndrome, but also direct serum testing for a specifi c germline mutation. The following surveillance testing is recommended for patients with a Lynch syndrome mutation or who meet clinical criteria for hereditary non-polyposis colorectal cancer, and at-risk family members. Management is based on test fi ndings.
Key points
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Colonoscopy: Performed in patients at age 20 to 25 years or 2 to 5 years before the earliest colorectal cancer if the affected family member was diagnosed before age 25 years. Repeat the colonoscopy every 1 to 2 years. If adenomas are not endoscopically resectable or have high-grade dysplasia, or if adenocarcinoma is found, a subtotal or total colectomy or total proctocolectomy is recommended based on the tumor location. Monitor any residual colon or rectum every 1 to 2 years.
Transvaginal ultrasound, endometrial sampling, CA-125 testing: Most institutions recommend these tests annually in women of childbearing age, starting at age 20 to 25 years, although these tests have not been shown to be sensitive or specifi c enough to recommend. Prophylactic hysterectomy with bilateral salpingo-oophorectomy is recommended in women who have completed childbearing.
Upper endoscopy (esophagogastroduodenoscopy or EGD): Although no clear statistics recommend this test, an EGD with extended duodenoscopy with consideration of a capsule endoscopy should be performed between age 30 to 35 years, and then every 2 to 3 years.
Urinalysis: Consider testing patients annually, starting at age 25 to 30 years.
Annual physical examination: Starting at age 25 to 30 years, to evaluate for central nervous system cancers.
FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
FAP is also autosomal dominant, but differs greatly from hereditary non-polyposis colorectal cancer in that the patient with FAP can have hundreds to thousands of adenomatous polyps in the colon (Figure 2) . These polyps are secondary to a germline mutation in the adenomatous polyposis coli (APC) gene. 10 Twenty percent of patients have a de novo mutation, meaning they are the fi rst person in their family identifi ed with the mutation. 10 If FAP is left untreated, colorectal cancer occurs earlier than normal, at a mean age of 39. 11 Patients with classic FAP have a near 100% risk of developing colorectal cancer in their lifetime.
11 APC gene testing is performed from a blood sample, and early surveillance is recommended in patients with APC mutations or a family history of phenotypical FAP. Flexible sigmoidoscopy or colonoscopy should be performed annually, beginning at age 10 to 15 years.
A total colectomy with ileorectal anastomosis or total proctocolectomy with an ileopouch anal anastomosis or ileostomy is recommended for patients with innumerable adenomatous polyps, a dysplastic polyp, or colorectal cancer. Surgery should be performed soon after diagnosis. Continued surveillance is important to reduce the risk of recurrent cancer and to detect advanced polyps. Endoscopic evaluation of the rectum every 6 to 12 months is recommended in patients who underwent total colectomy with ileorectal anastomosis. Patients who underwent an ileopouch anal anastomosis or ileostomy should have endoscopic evaluation of the ileal pouch or ileostomy every 1 to 3 years, with more frequent testing for large, fl at polyps that have villous or high-grade dysplasia.
Like Lynch syndrome, FAP carries extracolonic manifestations , so the patient's other organ systems should be screened ( Table 3) . The National Comprehensive Cancer Network (NCCN) recommends considering chemoprevention in the form of a nonsteroidal anti-infl ammatory drug (NSAID) in conjunction with endoscopic surveillance. 10 Recent studies have suggested that NSAIDs may inhibit tumor growth.
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ATTENUATED FAMILIAL ADENOMATOUS POLYPOSIS
Attenuated FAP (AFAP) also is associated with a mutation in the APC gene, but is differentiated by fewer adenomatous polyps (usually 10 to 100) and a frequent right-sided distribution of polyps. More importantly, AFAP carries a lower cancer risk and a later age of onset of adenomas and cancers (mean age is greater than 50 years). 10 APC gene testing is performed to confi rm the diagnosis. As with FAP, extracolonic manifestations also occur with upper gastrointestinal (GI) fi ndings and a thyroid cancer risk. Screening recommendations differ from those for FAP: Colonoscopy screening begins in the late teens, and then every 2 to 3 years until polyps are found. Once polyps are found, polypectomy is performed with continued surveillance every 1 to 2 years. Once polyposis is unmanageable or colorectal cancer is found, a total colectomy with ileorectal anastomosis or a total proctocolectomy with ileopouch anal anastomosis is recommended. As with classic FAP, once surgery is performed, any remaining rectum should be evaluated endoscopically every 6 to 12 months depending on the polyp burden.
Extracolonic surveillance consists of a baseline upper endoscopy with side-viewing duodenoscopy at age 25 to 30 years, with further recommendations based on the number of polyps and dysplastic polyps found. An annual physical examination and thyroid examination also are recommended.
MUTYH-ASSOCIATED POLYPOSIS
In 2002, MUTYH-associated polyposis (MAP) was identifi ed as associated with APC gene mutations. Patients with MAP have a 43% lifetime risk of developing colorectal cancer (or nearly 100% without adequate polyp surveillance). 13 Between 7% and 22% of patients with clinical FAP and 10% to 22% of patients with clinical AFAP have MAP. 13 Autosomal recessive, MAP occurs if one mutated gene is inherited from each parent. MAP is phenotypically similar to AFAP, in which the majority of patients have 10 to a few hundred adenomatous polyps. A patient can develop between 1 and 10 adenomas before age 40 years. However, some patients with MAP develop colorectal cancer without any polyposis. Three percent of patients who develop colorectal cancer before age 50 years have MUTYH mutations. 13, 14 Patients also may have hyperplastic polyposis.
Similar to AFAP, MAP has a median age of presentation of 45 to 59 years. Patients also are at risk for extracolonic tumors such as duodenal polyposis, but this occurs less frequently than in AFAP. Other late-onset malignancies can occur in the ovary, bladder, or skin. More recent studies are also noting thyroid abnormalities, such as nodules and papillary thyroid cancer. 13 The following surveillance testing for MAP is recommended; management is based on the fi ndings.
Colonoscopy: Performed every 1 to 2 years beginning at age 25 to 30 years. Suspicious polyps should be removed. If polyps are too large or too numerous to be managed endoscopically, a subtotal colectomy or total proctocolectomy is recommended. Continued surveillance of residual colon or rectum every 1 to 2 years is necessary.
Upper endoscopy with side-viewing duodenoscopy: Every 3 to 5 years beginning at age 30 to 35 years. Any duodenal polyps with dysplasia or villous changes should be removed. Depending on polyp size, number, and histology, endoscopy may be needed as often as every 6 months to 1 year.
Thyroid examination: Although no defi nite recommendations are established, yearly thyroid examinations are recommended. If abnormalities are found, refer the patient to a thyroid specialist.
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OTHER HEREDITARY COLON CANCER SYNDROMES
Other inherited colorectal cancer syndromes are beyond the scope of this article but are worth mentioning:
• Peutz-Jeghers syndrome, juvenile polyposis syndrome, and PTEN hamartoma tumor syndrome are characterized by GI hamartomatous polyps.
• Hereditary mixed polyposis syndrome consists of an increased risk for adenomas, juvenile polyps, hyperplastic polyps, and polyps with mixed histology.
• Hyperplastic polyposis syndrome, also called serrated polyposis, includes the presence of multiple hyperplastic polyps.
Refer to http://www.nccn.org for specifi c characteristics, screening, and management for these disorders.
OBTAINING AN ACCURATE FAMILY HISTORY
Taking the time to procure an accurate family history is vital to recognizing hereditary colorectal cancer. Obtain the history of the patient's fi rst-degree relatives and their second-degree relatives. Asking beyond this to include cousins can help detect generational patterns that are typical in hereditary syndromes. Remember to obtain the specifi c type of cancer, the age at diagnosis, and where the family member was treated (so that records may be checked if needed). If possible, ask the patient to speak upper endoscopy with side-viewing scope; consider MRI with or without CT.
• Gastric fundic gland polyps. Surveillance: upper endoscopy.
• Medulloblastoma, found in fewer than 2% of cases. Surveillance: annual physical examination.
• Papillary carcinoma of the thyroid, found in fewer than 2% of cases. Surveillance: annual thyroid examination, starting in late teenage years.
• Hepatoblastoma, found in children age 5 years and younger. No established recommendation but the following can be performed: liver palpitation, abdominal ultrasound, alpha-fetoprotein measurement every 3 to 6 months for 5 years.
• Pancreatic cancers, found in fewer than 1% of cases. No established recommendation for surveillance.
• Gastric cancers, found in fewer than 1% of cases. Surveillance: upper endoscopy. with relatives and get permission to obtain a copy of their pathology reports to confi rm malignancy. When discussing polyps, ask patients the number of polyps and the relative's age at diagnosis. Ask about the common extracolonic cancers that are associated with hereditary colorectal cancer (for example, uterine and stomach cancer, associated with Lynch syndrome). Obtain the age at diagnosis for any family members affected. An accurate family history will help clinicians recognize specifi c patterns of cancer in the patient's family, so they can determine recommended screening and refer the patient to a genetic counselor. 15 Testing is offered fi rst to the proband, the person who presents with a phenotypical pattern or has a pathologic diagnosis of cancer. When test results return, proper disclosure takes place. If a result is positive for a specifi c mutation, testing is offered to the family and recommended screening guidelines are provided for the patient and family. If a known mutation is found within the family and the family member's testing is negative, this family member can follow screening guidelines similar to an average-risk patient. If the proband's result is negative, but specifi c clinical criteria are present, screening guidelines for a specifi c syndrome may still be recommended. A variant of undetermined signifi cance also may be found, and recommendations may be based on the patient's personal or family history.
GENETIC COUNSELORS
The genetic counselor's role goes beyond disclosing results. The counselor also takes into account ethical considerations and can refer patients to psychological counseling if needed to cope with unfavorable news.
CONCLUSION
Primary care providers must recognize the clinical and pathological criteria of hereditary colorectal cancer so they can recommend the proper screening tests and refer patients to a genetic counselor. Obtaining an accurate personal and family history is essential. Features of hereditary colorectal cancer include multiple family members with the same or related types of cancer across generations, young age at time of diagnosis (under 50 years), patients with more than one primary cancer, rare cancers, multiple polyps, and cancers with certain pathological features. By screening patients and families early, healthcare providers can detect polyps and early cancerous lesions when they might be curable. JAAPA Earn Category I CME Credit by reading both CME articles in this issue, reviewing the post-test, then taking the online test at http://cme.aapa. org. Successful completion is defi ned as a cumulative score of at least 70% correct. This material has been reviewed and is approved for 1 hour of clinical Category I (Preapproved) CME credit by the AAPA. The term of approval is for 1 year from the publication date of January 2014.
